multi-epitope melanoma peptide vaccine
Vaccineexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2002 (NCT00089206)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- multi-epitope melanoma peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00705640 | Phase 1 | May 1, 2008 | National Cancer Institute (NCI), University of Virginia |
| NCT00071981 | Phase 2 | Mar 1, 2005 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), University of Virginia |
| NCT00118274 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2005 | National Cancer Institute (NCI), University of Virginia |
| NCT00118313 | Phase 1 | Nov 1, 2004 | National Cancer Institute (NCI), University of Virginia |
| NCT00085189 | Phase 2 | May 1, 2004 | National Cancer Institute (NCI), University of Southern California |
| NCT00089193 | Phase 2 | Sep 1, 2003 | National Cancer Institute (NCI), University of Virginia |
| NCT00089206 | Phase 2 | Aug 1, 2002 | National Cancer Institute (NCI), University of Virginia |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 0 | 2 | 2002 |
| University of Virginia | Academic/Hospital | 6 | 5 | 2 | 2002 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2004 |
4 organizations
Page 1 / 1